The purpose of this study was to define the prevalence of and risk factors for elevated serum alanine aminotransferase ( 
F ive-year survival rates following a diagnosis of childhood cancer have improved dramatically, with more than 80% now expected to reach this milestone.
(1) As a result, over 420,000 survivors of childhood cancer were estimated to be living in the United States in 2013, with anticipated growth of this population to 500,000 by 2020. (2) This progress has largely resulted from improvements in treatment regimens, some of which may cause hepatic injury. Abdominal irradiation can cause acute and/or chronic hepatic injury (3, 4) that may be potentiated by treatment with dactinomycin (4) or doxorubicin, (5) which modify the dose at which repair of sublethal radiation damage ceases. Several chemotherapeutic agents, including carmustine, (6) busulfan, (7, 8) melphalan, (9) conventional (10) and high-dose (11) methotrexate, mercaptopurine, (12) and asparaginase, used alone (13) or in combination, (14) can produce acute liver injury. Elevations of aspartate aminotransferase and/or alanine aminotransferase (ALT) may occur after major hepatic resections, (15) but prolonged liver dysfunction has not been reported. In addition, survivors may experience liver injury related to hepatitis virus infection, (16) iron overload, (17) and/or lifestyle factors, such as excessive alcohol use (18) or obesity. (19) The true prevalence of hepatic injury in long-term adult childhood cancer survivors (CCS) has not been well defined. Generalizability of outcomes reported in previous studies has been limited by the clinical heterogeneity of the cohorts studied and variable methods used to define hepatotoxicity. Although some studies have exclusively reported outcomes of survivors with chronic hepatitis (16) or treated with hematopoietic stem cell transplantation, (8) others have excluded these high-risk populations. (20) Definitions of hepatotoxicity have ranged from elevations of transaminases (e.g., ALT, aspartate aminotransferase) to abnormal liver synthetic function (prothrombin time, albumin) and pathological liver histology. Assessment of factors contributing to persistent treatment-related liver dysfunction has been limited by small cohort size and/ or lack of detailed treatment information (cumulative chemotherapy dose and hepatic radiation dosimetry). Moreover, the prevalence of clinically significant liver dysfunction in aging survivors and the potential impact of lifestyle factors and medication use on survivors' liver health are unknown.
Data regarding the prevalence of and risk factors for hepatic injury in CCS could inform both the initial treatment of future patients and the follow-up and management of current survivors. Thus, we undertook the present study to determine the prevalence of elevated ALT, a marker of hepatic injury, in a clinically assessed cohort of CCS whose prior chemotherapy and radiation therapy exposures, as well as current pharmaceutical use and lifestyle, were well characterized.
Patients and Methods
The current analysis uses the St. Jude Lifetime Cohort Study (SJLIFE). Eligibility for SJLIFE included (1) diagnosis of childhood malignancy treated at St. Jude Children's Research Hospital; (2) survival ≥10 years from diagnosis; and (3) current age ≥18 years. All patients included in the current analysis returned to the St. Jude Children's Research Hospital campus for a multiple-day evaluation, during which they underwent anthropometric measurements, measurement of markers of liver function and injury, dual energy X-ray absorptiometry, and other risk-based evaluations as indicated by previous treatment exposures. The detailed methods for ascertainment, recruitment, and evaluation of the members of this cohort have been reported previously. (21, 22) (23, 24) and of the institutional ULN (ULN = 40 for males and females) using the Common Terminology Criteria for Adverse Events version 4.03 (grade 0 ≤ ULN; grade 1 -> ULN to ≤3 × ULN; grade 2 ->3 ULN to ≤5 × ULN; grade 3 ->5 × ULN -≤20 × ULN; grade 4 ->20 x ULN). (25) Alkaline phosphatase was measured using the Cobas C system alkaline phosphatase according to International Federation of Clinical Chemistry and Laboratory Medicine Scientific Division, Committee on Reference Systems of Enzymes IFCC Generation 2 (ALP2; Roche Diagnostics, Indianapolis, IN) reagents on the Roche Cobas 6000 analyzer. The ULN was <131 U/L for females >15 years of age and males >19 years of age, and <261 U/L for males ≥18 and <19 years of age. High-density lipoprotein (HDL) cholesterol was measured using the Cobas C system HDL-Cholesterol plus 3rd generation (HDLC3; Roche Diagnostics, Indianapolis, IN). Triglycerides were measured using the Cobas C system triglycerides (TRIGL; Roche Diagnostics, Indianapolis, IN), and blood glucose was measured using the Cobas C system Glucose HK (GLUC3; Roche Diagnostics, Indianapolis, IN). Serum albumin was measured using the Cobas C system Albumin Gen.2 (ALB2; Roche Diagnostics, Indianapolis, IN) (Normal ≥ 3.8 g/dL). Serum total bilirubin was measured using the Bilirubin Total Gen.3 (BILT3; Roche Diagnostics, Indianapolis, IN) (Normal < 1.1 mg/dL). All assays were performed using the Cobas C501 system (Roche Diagnostics, Indianapolis, IN).
Screening for hepatitis B virus infection and immunity included measurement of anti-hepatitis B surface antigen antibody (Bio-Rad MONOLISA Anti-HBs EIA; Bio-Rad, Hercules, CA), total anti-hepatitis B core antigen immunoglobulin G/immunoglobulin M antibodies (MONOLISA TM Anti-HBc EIA, BioRad, Hercules, California) and hepatitis B surface antigen (Bio-Rad Genetic Systems HBsAg EIA; BioRad, Hercules, CA). Screening for hepatitis C virus infection included measurement of anti-hepatitis C virus encoded antigen antibody (ORTHO HCV Version 3.0 ELISA Test System; Ortho-Clinical Diagnostics, Raritan, NJ). All assays were performed using the Bio-Rad EVOLIS Automated EIA Processor (Bio-Rad, Hercules, CA).
aNtHropoMetrIC BoDy CoMpoSItIoN MeaSUreMeNtS
Anthropometric and body composition measurements were performed as previously described. (26) Height (in centimeters), weight (in kilograms), and waist circumference (in centimeters) at the narrowest point between the anterior superior iliac crest and the lowest rib were measured. Waist circumference was dichotomized for males (≤102 cm versus >102 cm) and females (≤88 cm versus >88 cm). (26) Body mass index was calculated as the weight (kg)/height (m) 2 . Individuals were classified as overweight if their body mass index was ≥25 kg/m 2 to <30 kg/m 2 and as obese if their body mass index was ≥30 kg/m 2 . Body weight was adjusted for those with amputated extremities. (27) Metabolic syndrome was defined by the presence of three or more of (1) abdominal obesity (waist circumference of >102 cm in males and >88 cm in females); (2) fasting triglycerides ≥150 mg/dL; (3) fasting HDL cholesterol <40 mg/dL in males and <50 mg/dL in females; (4) hypertension (systolic pressure ≥130 mm Hg or diastolic pressure ≥85 mm Hg) or current treatment with a pharmaceutical to lower blood pressure; and (5) fasting plasma glucose ≥100 mg/dL or current treatment with a pharmaceutical to lower blood sugar. (28) Dual energy X-ray absorptiometry and height were used to determine relative appendicular lean muscle mass, summing lean mass in arms and legs, and dividing by height in meters squared. Those with relative mass 1.5 standard deviations below age-, sex-, and race-specific values from the National Health and Nutrition Examination Study were classified as low lean muscle mass. (26) eXpoSUre DeFINItIoNS
Hepatotoxic therapy included the following surgical procedures: right hepatic lobectomy, extended right hepatic lobectomy, right hepatic trisegmentectomy, left hepatic lobectomy, extended left hepatic lobectomy, left hepatic trisegmentectomy, left lateral segmentectomy, and central hepatectomy. Hepatotoxic chemotherapy included methotrexate, mercaptopurine, thioguanine, asparaginase, carmustine, busulfan, dactinomycin, and doxorubicin. The definition of hepatotoxic radiation therapy was based on the Children's Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent and Young Adult Cancer. (29) eXpoSUre QUaNtIFICatIoN
The cumulative doses for 32 specific chemotherapeutic agents (5-azacytidine, bleomycin, busulfan, carboplatin, carmustine, cisplatinum, cyclophosphamide [intravenous or oral], cytarabine [intravenous, intramuscular, intrathecal, or subcutaneous], dacarbazine, dactinomycin, daunorubicin, dexamethasone, doxorubicin, etoposide [intravenous or oral], fludarabine, 5-fluorouracil, hydroxyurea, idarubicin, ifosfamide, asparaginase, lomustine, melphalan, methotrexate [intravenous, intramuscular, intrathecal or oral], nitrogen mustard, prednisone, procarbazine, teniposide, thioguanine, thiotepa, tretinoin, vinblastine, and vincristine), surgical procedures, and radiation treatment (fields, dose, and energy source) were abstracted from the medical records according to a protocol similar to that used in the Childhood Cancer Survivor Study. (30) High-dose methotrexate was defined as any single dose ≥1,000 mg/m 2 . (29) Radiation fields potentially involving the liver included the following: hepatic, renal, right or left upper quadrant, partial or entire spleen, paraaortic, right or left flank/hemiabdomen, whole abdomen, extended mantle, inverted Y, total lymphoid irradiation, subtotal lymphoid irradiation, and total body irradiation. Additional treatment volumes not included in the Children's Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent and Young Adult Cancer were evaluated, including spinal treatment volumes that included the lower thoracic and/or upper lumbar vertebral bodies. Hepatic radiotherapy dose was quantified by reconstructing each patient's individual radiation treatment on a computed tomography-based phantom with an organ library for calculation of normal organ radiation doses. For each patient's reconstructed radiation treatment plan, the volumetric dose to the liver was calculated by recreating the treatment ports and actual beam energies in a modern radiation therapy planning software system (Eclipse; Varian Medical Systems, Milpitas, CA). The volumes of liver receiving 10 Gy (V10), 15 Gy (V15), and 20 Gy (V20) were used in our analysis as both dichotomous (yes/no) and continuous (per 10% of liver volume) variables.
Risky drinking was defined in the National Institute for Alcohol Abuse and Alcoholism physicians' guidelines as drinking for women that exceeds three drinks per day or seven drinks per week, and for men as more than four drinks per day or 14 drinks per week. (31, 32) Heavy drinking was defined as five or more drinks per day for women and six or more drinks per day for men at least once a month in the past year. (33, 34) Hepatotoxic pharmaceuticals were defined as those pharmaceuticals that produced drug-induced liver injury in ≥1% of reported patients who survived without liver transplantation 6 months after the acute drug-induced liver injury with evidence of either chronic or no chronic liver injury. (35) Current use of atorvastatin, rosuvastatin, simvastatin, duloxetine, amoxicillin, amoxicillin with clavulanic acid, azithromycin, ciprofloxacin, levofloxacin, minocycline, nitrofurantoin, sulfamethoxazole with trimethoprim, terbinafine, isoniazid, lamotrigine, phenytoin, or diclofenac was abstracted from the SJLIFE Clinic Note. Current use of over-the-counter medications or herbal preparations was not included because such use could not be documented reliably.
StatIStICal aNalySIS
Descriptive statistics were used to summarize demographic and treatment variables for participants and nonparticipants. The chi-squared test was used to compare categorical variables and the t test was used to compare continuous variables between these two groups.
Given little a priori justification for including a particular set of covariates in the model, to adjust for confounding bias, Elastic Net was applied to all demographic, lifestyle, and treatment variables to perform model selection for elevated ALT using the GLMNET in R 3.2.2. (36, 37) Models with the smallest Akiake Information Criterion were selected as the final models.
Modified Poisson regression models (Poisson regression with a robust error variance) (38, 39) were used to identify risk factors for elevated ALT on models selected by using Elastic Net. This approach produces unbiased parameter estimates and improves the prediction of error. Results for ALT were presented as relative risks with 95% confidence intervals (CI). These analyses were conducted using Statistical Analysis System software (SAS 9.4; SAS Institute, Cary, NC). (Fig. 1) . The evaluable cohort included 48.7% female and 82.6% non-Hispanic white participants. The 1,668 nonparticipants were more likely to be male and non-Hispanic black. Fewer nonparticipants were diagnosed with acute lymphoblastic leukemia, and fewer had been treated with Erwinia or Escherichia coli l-asparaginase, high-dose methotrexate, or mercaptopurine (Tables 1 and 2 ). The median age of the participants at diagnosis was 7.4 years, the median age at evaluation was 31.4 years, and the median elapsed time from diagnosis to evaluation was 23.2 years (Table 1) . Table 3 summarizes additional characteristics of the cohort.
Results
Use of hepatotoxic pharmaceuticals is detailed in Table 4 . Among the potentially hepatotoxic medications analyzed, liver injury was associated with use of several 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors ("statins"), phenytoin, and lamotrigine, whether evaluated using the sex-specific definitions of the ULN (Table 4) or the institutional ULN (Supporting Table S1 ). Among patients who received hepatic irradiation, the median percentage of the liver that received 10 Gy, 15 Gy, and 20 Gy was 48.8%, 26.6%, and 20.7%, respectively (Table 5) .
Participants were considered at risk for hepatitis B if they were diagnosed prior to 1972, and at risk for hepatitis C if they were diagnosed prior to 1993. Of 1,592 participants at risk, 14 had not been screened for hepatitis C. Of the 1,578 who were screened, 98 (6.2%) were seropositive. Of 93 participants at risk, 20 were not screened for hepatitis B. Of the 73 who were screened, 7 (9.6%) were seropositive.
ALT >ULN, using the sex-specific ULN values, was identified in 1,137 (41.3%) survivors. Five hundred eighty-one were male and 556 were female. Among males, 541 (38.3 %) had grade 1, 27 (1.9%) had grade 2, 13 (0.9%) had grade 3, and none had grade 4 ALT. Among females, 517 (38.6 %) had grade In multivariable models, non-Hispanic, white race/ethnicity, age at evaluation in years, body mass index ≥25 kg/m 2 , metabolic syndrome, current treatment with atorvastatin or rosuvastatin or simvastatin, hepatitis C virus infection, prior treatment with busulfan or thioguanine, and history of hepatic surgery were all significant risk factors for elevated ALT. Radiation therapy dosimetric variables V10, V15, and V20 (by 10% volume increment) achieved statistical significance in the multivariable models (Table 6 ).
Multivariable models using both the Children's Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent and Young Adult Cancer definitions for hepatic irradiation, and an expanded definition that included T11 through L3 spinal irradiation volumes provided comparable results (Supporting Table S3 ).The results of the Standardized Pearson Test for Goodness of Fit demonstrate that the models developed fit the available data well (Supporting Table S4 ).
CaUSe oF DeatH
The causes of death among 1,225 deceased individuals eligible for SJLIFE were reviewed. For 17 of these (1.4%), liver disease was a significant factor contributing to death. The details regarding these 17 individuals are shown in Supporting Table 5 . 
Discussion
Acute hepatic injury is frequently observed during treatment of childhood cancer, but its persistence and impact on liver health during adulthood have not been well studied. With more precise assessment of hepatotoxic chemotherapy and radiation exposures, we have characterized liver injury related to lifestyle factors and medication use in adults followed for more than 20 years after childhood cancer diagnosis. The prevalence of liver injury in our cohort as measured by elevated ALT was 41.3% using sex-specific values for ULN, and was substantially higher than either 15.2% using our institutional unisex ULN or 5.8% among a younger group of Dutch CCS with shorter follow-up. (20) ALT elevations were generally low grade in severity, which may be related to progress in pediatric cancer therapeutic strategies and advances in supportive care. We identify several treatment and post-treatment factors that increase the risk for liver injury during adulthood.
Radiation therapy doses to the liver have been intentionally minimized to the lowest effective dose and smallest volume to reduce injury. No prior study has evaluated the dose or volume relationships between prior hepatic irradiation and evidence of liver injury among aging survivors of childhood cancer. The current study identified a significant association between the percentage of the liver treated with ≥10 Gy, ≥15 Gy, or ≥20 Gy and elevated ALT. This excess risk for liver injury was also observed in individuals who received spinal radiation at the level of T11-L3, a field not previously identified as one that exposes the liver. Future updates to screening guidelines should consider including T11-L3 spinal irradiation.
Aging survivors develop chronic health conditions at higher rates compared with those of noncancer control populations, some of which require management with potentially hepatotoxic medications. (21, 40) A finding in the present study was the association of current treatment with one of three commonly prescribed "statins" with an increased risk for liver injury among SJLIFE participants. In the general population, elevations of serum levels of ALT are reported in <1% of patients receiving "statins" with the exception of atorvastatin, where a frequency of 2% to 3% has been reported among patients treated with 80 mg/ day. (41, 42) In our cohort, almost one in two survivors taking a statin had ALT elevations. These data suggest that survivors may be more vulnerable to statin-related liver injury, possibly related to prior, treatment-related hepatic injury.
Prior treatment with busulfan, a frequent component of hematopoietic stem cell transplantation conditioning regimens, and thioguanine were independently associated with an increased risk for grades 1-4 ALT. Hematopoietic stem cell transplantation complications, such as sinusoidal obstruction syndrome/veno-occlusive disease and graft-versus-host disease, may also produce liver injury. (43, 44) This group of survivors, excluded from prior large studies of hepatic injury among CCS, warrant particularly careful evaluation and follow-up. Metabolic syndrome is defined by a composite of modifiable health and lifestyle factors. Larger waist circumference and overweight/obesity are associated with an increased risk of elevated ALT. (19) The prevalence of nonalcoholic fatty liver disease among participants in the National Health and Nutrition Examination Study III, defined by the presence of moderate to severe hepatic steatosis with normal ALT and aspartate aminotransferase, was 16.4%. (45) These data suggest that interpretation of the results of the current study must be cautious, because the known higher prevalence of overweight/obesity (46, 47) and visceral adiposity (48) among CCS may be associated with the presence of nonalcoholic fatty liver disease with a normal ALT. Evaluation using ultrasound (45) or other noninvasive methods for categorizing hepatic steatosis may provide a more definitive picture of the prevalence of liver injury among childhood cancer survivors.
Heavy drinking was not identified as an independent risk factor for liver injury in our cohort when the data were analyzed using sex-specific values for ULN. A previous report showed that consumption of more than 14 units/week was associated with an odds ratio = 2.53 (95% CI, 1.04, 6.18) for elevated ALT. (20) This level of alcohol consumption was endorsed by 5.9% of the Dutch cohort and by 21.5% of the SJLIFE cohort. In another study, 24.0% of those who drank more than two drinks/day had an elevated ALT, but a dose-response relationship could not be demonstrated. (38) Survivors should be counseled about the potential for alcohol to exacerbate their underlying liver injury from complications associated with cancer treatment. CCS with chronic hepatitis B or C infection, most of whom were treated prior to routine testing of blood products for these viruses, (16, 49) represent a group that is particularly vulnerable to additional hepatotoxic insults as they age. In the SJLIFE cohort, prior infection with hepatitis C virus was associated with an almost 2-fold increased risk of elevated ALT. Non-Hispanic, white race/ethnicity was associated with an increased risk for elevated ALT compared with non-Hispanic, black race/ethnicity, a finding previously noted during treatment for acute lymphoblastic leukemia. (50) A potential limitation of this study is that 38% of the eligible survivors did not have an ALT value and nonparticipants did differ from participants on some demographic characteristics and cancer diagnoses. Thus, the potential exists that the rate of elevated ALT could be different among nonparticipants. In addition, this is a retrospective cohort study in which data for some variables, such as hepatitis B Upper limit of normal = 30 U/L for males and = 19 U/L for females. Abbreviations: ALT, alanine aminotransferase; CI, confidence interval; COG, Children's Oncology Group; RR, relative risk; V10, percentage of the liver treated to ≥10 Gray; V15, percentage of the liver treated to ≥15 Gray; V20, percentage of the liver treated to ≥20 Gray.
and C virus status, fasting blood sugar, HDL, and triglycerides were incomplete. We do not have liver imaging to identify findings consistent with hepatic steatosis, cirrhosis, or portal hypertension. However, this study has several important strengths, including large size, prolonged follow-up (median, 23.2 years), detailed exposure data including radiation dosimetry and prescription pharmaceutical use, and comprehensive clinical assessment including measurement of body composition.
In conclusion, a significant minority of adults treated for cancer during childhood have an elevated ALT, a marker of liver injury, related to specific cancer treatments, treatment complications, medications, and health and lifestyle factors. Although contemporary treatment strategies aim to limit hepatotoxic therapy, CCS should be counseled about the risk of additional insults to liver health as they age. Future research should define the prevalence of nonalcoholic steatosis and steatohepatitis in CCS, which may interact with both prior therapeutic exposures and current pharmaceutical use and lifestyle choices, to produce liver injury not associated with elevations of ALT, and which may be amenable to intervention.
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